Why is Anamorelin banned in some areas?

Anamorelin(Anamorelin) is an oral orexigenic drug mainly used to treat patients with cancer wasting syndrome (Cancer Cachexia, CAC) to improve weight loss and muscle loss. However, in some countries and regions, the marketing of anamorelin is strictly restricted or even banned, mainly because the safety data of the drug are insufficient and the evidence of efficacy is still limited.

Anamulin's mechanism of action is through selective activation of the growth hormone-releasing peptide (Ghrelin) receptor, thereby stimulating appetite, increasing energy intake and improving lean body mass. However, this effect may also be accompanied by metabolic and cardiovascular risks, such as increased blood sugar, arrhythmias, blood pressure fluctuations, and abnormalities in liver function indicators. In highly regulated countries, if a drug has insufficient long-term safety data or clinical trial sample sizes are limited, regulators will often delay approval or require restricted use to ensure patient safety.

In addition, anamorelin may cause side effects such as edema or gastrointestinal discomfort during clinical use. The risk of these adverse reactions is higher in special groups such as patients with diabetes, heart disease, or liver dysfunction. Due to these potential risks, drug regulatory agencies in some regions have not yet approved the marketing of anamorelin, but require further clinical data to support long-term safety and effectiveness.

In my country, anamorelin has not yet been approved for marketing. Patients need to obtain it through overseas channels, such as the original Japanese version. However, its use must strictly follow the doctor's prescription and undergo regular monitoring, including weight, electrocardiogram, blood sugar and liver function, to ensure the safety and effectiveness of the drug. Patients should avoid adjusting the dosage on their own or using it without monitoring for a long time to avoid adverse events.

In general, the marketing restrictions of anamorelin more reflect a cautious attitude towards patient safety rather than the lack of efficacy of the drug itself. It still has potential value in specific groups, but must be used within a scientific and safety framework.

Reference materials:https://pmc.ncbi.nlm.nih.gov/articles/PMC4677053/